Provided by Tiger Trade Technology Pte. Ltd.

Exelixis

54.08
+0.39000.73%
Post-market: 54.080.00000.00%19:44 EDT
Volume:1.95M
Turnover:105.64M
Market Cap:13.40B
PE:17.01
High:54.68
Open:53.74
Low:53.70
Close:53.69
52wk High:57.57
52wk Low:33.76
Shares:247.78M
Float Shares:214.00M
Volume Ratio:0.93
T/O Rate:0.91%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.18
EPS(LYR):2.78
ROE:44.39%
ROA:23.97%
PB:7.27
PE(LYR):19.45

Loading ...

13D Filings

Dow Jones
·
Yesterday

EXEL INDUSTRIES Updates Market on Share Capital and Voting Rights

TIPRANKS
·
Aug 20

BMO starts Exelixis at Market Perform into patent cliff

TIPRANKS
·
Aug 19

Exelixis Director Mary C Beckerle Disposes of 9,812 Shares Worth $526,908.92

Reuters
·
Aug 13

Exelixis (EXEL) Earnings Strength Meets Lower Guidance As Valuation Comes Back Into View

Simply Wall St.
·
Aug 12

Exelixis Earnings Call: Cabo Strength, Zanza Awaited

TIPRANKS
·
Aug 08

U.S. Research Roundup-Airbnb, Expedia Group, Parker-Hannifin

Reuters
·
Aug 07

Guggenheim Keeps Their Hold Rating on Exelixis (EXEL)

TIPRANKS
·
Aug 07

Exelixis Inc : Leerink Partners Cuts to Market Perform from Outperform

THOMSON REUTERS
·
Aug 07

Leerink downgrades Exelixis to Market Perform following Q2 results

TIPRANKS
·
Aug 07

Exelixis Targets Residual Colorectal Cancer With New Phase 3 Trial

TIPRANKS
·
Aug 07

Movement Alert|Exelixis Falls 5.7% in Regular Trading, Post-Earnings Profit-Taking Drives Sell-Off

Market Focus
·
Aug 07

Exelixis Price Target Cut to $52.00/Share from $56.00 by Truist Securities

Dow Jones
·
Aug 07

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (LLY), Exelixis (EXEL) and Moderna (MRNA)

TIPRANKS
·
Aug 06

Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)

TIPRANKS
·
Aug 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA), Exelixis (EXEL) and Editas Medicine (EDIT)

TIPRANKS
·
Aug 06

Exelixis Inc Reports Results for the Quarter Ended March 31 - Earnings Summary

Reuters
·
Aug 06

Exelixis Q2 FY26 GAAP Net Income Rises 14.72% to $212.1 Million; Revenue Increases 10.63% to $628.7 Million

Reuters
·
Aug 06

Exelixis Q2 Revenue Misses Analyst Estimates, Lowers 2026 Outlook

Reuters
·
Aug 06

Exelixis Q2 Adjusted Earnings, Revenue Rise; Shares Drop After Hours

MT Newswires Live
·
Aug 06